A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout - Concepedia

Concepedia

Publication | Closed Access

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout

184

Citations

30

References

2008

Year

M.K. Reinders, C.J. Haagsma, Tim Jansen, Eric N. van Roon, J Delsing, Mart A F J van de Laar, J. R. B. J. Brouwers

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1